Buy Vabysmo (faricimab-svoa)

What is Vabysmo (faricimab-svoa) for?

Vabysmo (faricimab-svoa) is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of:^[1]

• Neovascular or “wet” age-related macular degeneration (nAMD)
• Diabetic macular edema (DME)

It is available in single-dose vial form, containing 120 mg/mL faricimab-svoa.^[1]

How does Vabysmo (faricimab-svoa) work?

Neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) are the two leading causes of vision loss. The proteins angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) have been found to play an important role in the development of these diseases. They lead to vision loss by destabilising blood vessels, causing new leaky blood vessels to form and increasing inflammation.^[2]

The active ingredient in Vabysmo, faricimab-svoa, is a bispecific antibody. It can bind to and block pathways linked to Ang-2 and VEGF-A. By doing so, Vabysmo can stabilise blood vessels and is thought to improve and maintain vision.^[3]

Where has Vabysmo (faricimab-svoa) been approved?

Vabysmo (faricimab-svoa) was approved for the treatment of nAMD and DME by:^[4]

• The Food and Drug Administration (FDA), USA on January 28, 2021.

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Vabysmo (faricimab-svoa) taken?

The standard dosage is:^[1]

• The first 4 doses: 6 mg given by intravitreal (injection into the eye) injection every 4 weeks
• Then at a schedule determined after clinical evaluation

Vabysmo (faricimab-svoa) should not be used during pregnancy unless the potential benefit to the patient outweighs the potential risk to the unborn baby.^[1]

Complete information about Vabysmo (faricimab-svoa) dosage and administration can be found in the official prescribing information listed in our references section.^[1]

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Vabysmo (faricimab-svoa)?

Common adverse reactions

The most common side effects (≥5% of patients) listed in the prescribing information include:^[1]

• Conjunctival hemorrhage

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include:^[1]

• Hypersensitivity
• Endophthalmitis and retinal detachments
• Increase in intraocular pressure
• Thromboembolic events

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.^[1]

References

1. Full prescribing information [FDA]: Vabysmo (faricimab-svoa) [PDF]
Roche, Jan 2022

2. Facts about age-related macular degeneration and diabetic eye disease
National Eye Institute, cited Jan 2022

3. The Mechanism of the Bispecific Antibody Faricimab
Retinal Physician, Mar 2019

4. FDA approves Roche’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Roche press release, Jan 2022